Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Published byJere Jurkka Modified over 5 years ago

Similar presentations

Presentation on theme: "Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,"— Presentation transcript:

1 Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age, gender, drugs for comorbidities (1/0), oral glucocorticosteroids (1/0) and use of non-steroidal anti-inflammatory drugs. *Number of patients per visit. bDMARD, biological disease-modifying antirheumatic drug; DAS28, 28-joint Disease Activity Score; MTX, methotrexate; RAPID3 (0–30), Routine Assessment of Patient Index Data (three domains: functioning, pain, patient global). Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age, gender, drugs for comorbidities (1/0), oral glucocorticosteroids (1/0) and use of non-steroidal anti-inflammatory drugs. *Number of patients per visit. bDMARD, biological disease-modifying antirheumatic drug; DAS28, 28-joint Disease Activity Score; MTX, methotrexate; RAPID3 (0–30), Routine Assessment of Patient Index Data (three domains: functioning, pain, patient global)‏ Niels W. Boone et al. RMD Open 2019;5:e000836 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,"

Similar presentations

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.
(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.
Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.
Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)
Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.
Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.

Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.
Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.
ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Similar presentations

Ads by Google